Literature DB >> 23365458

Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56(bright) subset.

Emily M Mace1, Amy P Hsu, Linda Monaco-Shawver, George Makedonas, Joshua B Rosen, Lesia Dropulic, Jeffrey I Cohen, Eugene P Frenkel, John C Bagwell, John L Sullivan, Christine A Biron, Christine Spalding, Christa S Zerbe, Gulbu Uzel, Steven M Holland, Jordan S Orange.   

Abstract

Mutations in the transcription factor GATA2 underlie the syndrome of monocytopenia and B- and natural killer (NK)-cell lymphopenia associated with opportunistic infections and cancers. In addition, patients have recurrent and severe viral infections. NK cells play a critical role in mediating antiviral immunity. Human NK cells are thought to mature in a linear fashion, with the CD56(bright) stage preceding terminal maturation to the CD56(dim) stage, considered the most enabled for cytotoxicity. Here we report an NK cell functional defect in GATA2-deficient patients and extend this genetic lesion to what is considered to be the original NK cell-deficient patient. In most cases, GATA2 deficiency is accompanied by a severe reduction in peripheral blood NK cells and marked functional impairment. The NK cells detected in peripheral blood of some GATA2-deficient patients are exclusively of the CD56(dim) subset, which is recapitulated on in vitro NK cell differentiation. In vivo, interferon α treatment increased NK cell number and partially restored function but did not correct the paucity of CD56(bright) cells. Thus, GATA2 is required for the maturation of human NK cells and the maintenance of the CD56(bright) pool in the periphery. Defects in GATA2 are a novel cause of profound NK cell dysfunction.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23365458      PMCID: PMC3617632          DOI: 10.1182/blood-2012-09-453969

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

1.  Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature.

Authors:  Jan Kazenwadel; Genevieve A Secker; Yajuan J Liu; Jill A Rosenfeld; Robert S Wildin; Jennifer Cuellar-Rodriguez; Amy P Hsu; Sarah Dyack; Conrad V Fernandez; Chan-Eng Chong; Milena Babic; Peter G Bardy; Akiko Shimamura; Michael Y Zhang; Tom Walsh; Steven M Holland; Dennis D Hickstein; Marshall S Horwitz; Christopher N Hahn; Hamish S Scott; Natasha L Harvey
Journal:  Blood       Date:  2011-12-06       Impact factor: 22.113

2.  Bilateral adrenal EBV-associated smooth muscle tumors in a child with a natural killer cell deficiency.

Authors:  Rachel K Shaw; Andrew C Issekutz; Robert Fraser; Pierre Schmit; Barb Morash; Linda Monaco-Shawver; Jordan S Orange; Conrad V Fernandez
Journal:  Blood       Date:  2012-03-16       Impact factor: 22.113

3.  Cis-element mutated in GATA2-dependent immunodeficiency governs hematopoiesis and vascular integrity.

Authors:  Kirby D Johnson; Amy P Hsu; Myung-Jeom Ryu; Jinyong Wang; Xin Gao; Meghan E Boyer; Yangang Liu; Youngsook Lee; Katherine R Calvo; Sunduz Keles; Jing Zhang; Steven M Holland; Emery H Bresnick
Journal:  J Clin Invest       Date:  2012-09-10       Impact factor: 14.808

4.  CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia.

Authors:  Joris M van Montfrans; Andy I M Hoepelman; Sigrid Otto; Marielle van Gijn; Lisette van de Corput; Roel A de Weger; Linda Monaco-Shawver; Pinaki P Banerjee; Elisabeth A M Sanders; Cornelia M Jol-van der Zijde; Michael R Betts; Jordan S Orange; Andries C Bloem; Kiki Tesselaar
Journal:  J Allergy Clin Immunol       Date:  2011-12-24       Impact factor: 10.793

5.  Strong alpha beta and gamma delta TCR response in a patient with disseminated Mycobacterium avium infection and lack of NK cells and monocytopenia.

Authors:  T Wendland; S Herren; N Yawalkar; A Cerny; W J Pichler
Journal:  Immunol Lett       Date:  2000-05-01       Impact factor: 3.685

6.  GATA2 haploinsufficiency caused by mutations in a conserved intronic element leads to MonoMAC syndrome.

Authors:  Amy P Hsu; Kirby D Johnson; E Liana Falcone; Rajendran Sanalkumar; Lauren Sanchez; Dennis D Hickstein; Jennifer Cuellar-Rodriguez; Jacob E Lemieux; Christa S Zerbe; Emery H Bresnick; Steven M Holland
Journal:  Blood       Date:  2013-03-15       Impact factor: 22.113

7.  Combined immunodeficiency with life-threatening EBV-associated lymphoproliferative disorder in patients lacking functional CD27.

Authors:  Elisabeth Salzer; Svenja Daschkey; Sharon Choo; Michael Gombert; Elisangela Santos-Valente; Sebastian Ginzel; Martina Schwendinger; Oskar A Haas; Gerhard Fritsch; Winfried F Pickl; Elisabeth Förster-Waldl; Arndt Borkhardt; Kaan Boztug; Kirsten Bienemann; Markus G Seidel
Journal:  Haematologica       Date:  2012-07-16       Impact factor: 9.941

8.  Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia.

Authors:  Christopher N Hahn; Chan-Eng Chong; Catherine L Carmichael; Ella J Wilkins; Peter J Brautigan; Xiao-Chun Li; Milena Babic; Ming Lin; Amandine Carmagnac; Young K Lee; Chung H Kok; Lucia Gagliardi; Kathryn L Friend; Paul G Ekert; Carolyn M Butcher; Anna L Brown; Ian D Lewis; L Bik To; Andrew E Timms; Jan Storek; Sarah Moore; Meryl Altree; Robert Escher; Peter G Bardy; Graeme K Suthers; Richard J D'Andrea; Marshall S Horwitz; Hamish S Scott
Journal:  Nat Genet       Date:  2011-09-04       Impact factor: 38.330

9.  Human natural killer cell maturation defect supports in vivo CD56(bright) to CD56(dim) lineage development.

Authors:  Carolina Inés Domaica; Mercedes Beatriz Fuertes; Ignacio Uriarte; María Victoria Girart; Jessica Sardañons; Dorina Ileana Comas; Daniela Di Giovanni; María Isabel Gaillard; Liliana Bezrodnik; Norberto Walter Zwirner
Journal:  PLoS One       Date:  2012-12-11       Impact factor: 3.240

10.  GATA-2 plays two functionally distinct roles during the ontogeny of hematopoietic stem cells.

Authors:  Kam-Wing Ling; Katrin Ottersbach; Jan Piet van Hamburg; Aneta Oziemlak; Fong-Ying Tsai; Stuart H Orkin; Rob Ploemacher; Rudi W Hendriks; Elaine Dzierzak
Journal:  J Exp Med       Date:  2004-10-04       Impact factor: 14.307

View more
  102 in total

Review 1.  Harnessing adaptive natural killer cells in cancer immunotherapy.

Authors:  Lisa L Liu; Aline Pfefferle; Vincent Oei Yi Sheng; Andreas T Björklund; Vivien Béziat; Jodie P Goodridge; Karl-Johan Malmberg
Journal:  Mol Oncol       Date:  2015-10-20       Impact factor: 6.603

Review 2.  Natural killer cell deficiency.

Authors:  Jordan S Orange
Journal:  J Allergy Clin Immunol       Date:  2013-09       Impact factor: 10.793

3.  GATA2 deficiency and human hematopoietic development modeled using induced pluripotent stem cells.

Authors:  Moonjung Jung; Stefan Cordes; Jizhong Zou; Shiqin J Yu; Xavi Guitart; So Gun Hong; Vinh Dang; Elaine Kang; Flavia S Donaires; Sergio A Hassan; Maher Albitar; Amy P Hsu; Steven M Holland; Dennis D Hickstein; Danielle Townsley; Cynthia E Dunbar; Thomas Winkler
Journal:  Blood Adv       Date:  2018-12-11

4.  Association of GATA2 Deficiency With Severe Primary Epstein-Barr Virus (EBV) Infection and EBV-associated Cancers.

Authors:  Jeffrey I Cohen; Lesia Dropulic; Amy P Hsu; Christa S Zerbe; Tammy Krogmann; Kennichi Dowdell; Ronald L Hornung; Jana Lovell; Nancy Hardy; Dennis Hickstein; Edward W Cowen; Katherine R Calvo; Stefania Pittaluga; Steven M Holland
Journal:  Clin Infect Dis       Date:  2016-05-11       Impact factor: 9.079

Review 5.  Emerging insights into human health and NK cell biology from the study of NK cell deficiencies.

Authors:  Emily M Mace; Jordan S Orange
Journal:  Immunol Rev       Date:  2019-01       Impact factor: 12.988

6.  Resolution of Multifocal Epstein-Barr Virus-Related Smooth Muscle Tumor in a Patient with GATA2 Deficiency Following Hematopoietic Stem Cell Transplantation.

Authors:  Mark Parta; Jennifer Cuellar-Rodriguez; Alexandra F Freeman; Juan Gea-Banacloche; Steven M Holland; Dennis D Hickstein
Journal:  J Clin Immunol       Date:  2016-12-06       Impact factor: 8.317

Review 7.  Clinical utility of natural killer cells in cancer therapy and transplantation.

Authors:  David A Knorr; Veronika Bachanova; Michael R Verneris; Jeffrey S Miller
Journal:  Semin Immunol       Date:  2014-03-05       Impact factor: 11.130

Review 8.  Emerging insights into natural killer cells in human peripheral tissues.

Authors:  Niklas K Björkström; Hans-Gustaf Ljunggren; Jakob Michaëlsson
Journal:  Nat Rev Immunol       Date:  2016-04-28       Impact factor: 53.106

Review 9.  Primary immunodeficiency update: Part II. Syndromes associated with mucocutaneous candidiasis and noninfectious cutaneous manifestations.

Authors:  Dominique C Pichard; Alexandra F Freeman; Edward W Cowen
Journal:  J Am Acad Dermatol       Date:  2015-09       Impact factor: 11.527

10.  Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations.

Authors:  Alexander Vargas-Hernández; Emily M Mace; Ofer Zimmerman; Christa S Zerbe; Alexandra F Freeman; Sergio Rosenzweig; Jennifer W Leiding; Troy Torgerson; Matthew C Altman; Edith Schussler; Charlotte Cunningham-Rundles; Ivan K Chinn; Alexandre F Carisey; Imelda C Hanson; Nicholas L Rider; Steven M Holland; Jordan S Orange; Lisa R Forbes
Journal:  J Allergy Clin Immunol       Date:  2017-10-27       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.